Why Merrimack Pharmaceuticals Inc. Shares Are Less Merry

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Merrimack Pharmaceuticals (NASDAQ: MACK  ) , a biopharmaceutical company focused on developing cancer therapies, fell as much as 23% after reporting results from a mid-stage study involving MM-121 in combination with Paclitaxel for the treatment of platinum-resistant or refractory-advanced ovarian cancer.

So what: According to Merrimack's press release, MM-121, which is being developed in collaboration with Sanofi (NYSE: SNY  ) , did not meet its primary endpoint of improving progression-free survival in a mid-stage trial. The hazard ratio of 1 signifies that there was no statistical difference between the MM-121 with Paclitaxel arm and the control arm with just Paclitaxel. In addition, certain side effects like diarrhea and vomiting were more prevalent in the group taking MM-121. If there was a bright spot, it was that a certain subset of patients with two specific biomarkers did demonstrate a hazard ratio for PFS of 0.37, signifying a 63% improvement over the Paclitaxel control arm, and may encourage new research geared toward patients with these biomarkers.

Now what: The development of MM-121 is still very much in the early stages, but today's news certainly wasn't encouraging. There was no benefit demonstrated via the hazard ratio compared to the control, and the increase in side effects relative to the control arm is to me a bit concerning. Merrimack and Sanofi could certainly still find success with MM-121 as the biomarker subset showed, but I'd rather wait on the sidelines for Merrimack to deliver solid late-stage results than be left pondering what happened on a day like today.

Two revolutionary biotechs you should be watching instead
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2705938, ~/Articles/ArticleHandler.aspx, 9/29/2016 6:19:30 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 8 hours ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
MACK $6.20 Up +0.05 +0.81%
Merrimack Pharmace… CAPS Rating: ***
SNY $38.67 Up +0.52 +1.36%
Sanofi CAPS Rating: *****